CJC-1295 is one of the most searched research peptides in the market — and for good reason. It sits at the intersection of growth hormone biology and peptide engineering, representing one of the more technically sophisticated approaches to extending the activity of a naturally occurring hormone analog in research models.
It’s a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) — the hypothalamic signal that tells the pituitary gland to release growth hormone. What makes CJC-1295 particularly interesting to researchers is not just what it targets, but how it was engineered to do it far more effectively than native GHRH ever could.
Research Use Educational Framework
- Educational reference content only
- Structural stability awareness
- Environmental handling considerations
- Analytical quality and purity awareness
- Non-clinical research context
The GHRH System: What CJC-1295 Targets
To understand CJC-1295, you first need to understand the biological system it works within. Growth Hormone-Releasing Hormone (GHRH) is produced in the hypothalamus and travels to the anterior pituitary gland, where it binds to GHRH receptors on somatotroph cells — the cells responsible for producing and releasing growth hormone (GH).
When GHRH binds its receptor, it triggers a signaling cascade that results in GH secretion into the bloodstream. GH then acts on the liver and peripheral tissues to stimulate the production of Insulin-like Growth Factor 1 (IGF-1), which mediates many of GH’s downstream effects on tissue growth, metabolism, and cellular repair.
The problem with native GHRH as a research tool is the same problem that affects most naturally occurring peptide hormones — it’s broken down rapidly in circulation by an enzyme called dipeptidyl peptidase-4 (DPP-4), giving it a half-life of just a few minutes. That makes it impractical for sustained research protocols. CJC-1295 was engineered specifically to solve this problem. For foundational context on how peptides interact with biological signaling systems, our Peptide Mechanisms and Signaling Pathways guide covers the key concepts.
The Engineering Behind CJC-1295: DAC Technology
CJC-1295 is built on the first 29 amino acids of native GHRH — the biologically active fragment responsible for receptor binding. What makes it distinct is the addition of a Drug Affinity Complex (DAC) — a lysine residue modified with a maleimidopropionic acid group that allows CJC-1295 to covalently bind to albumin in the bloodstream.
This albumin-binding mechanism is the key to CJC-1295’s extended half-life. Once in circulation, CJC-1295 binds to albumin — the most abundant plasma protein — which protects it from enzymatic degradation and renal clearance. The result is a half-life of approximately 6–8 days, compared to minutes for native GHRH. This makes CJC-1295 with DAC suitable for research protocols requiring sustained GHRH receptor stimulation over extended timeframes.
It’s worth noting that a related compound — CJC-1295 without DAC, also known as Modified GRF(1-29) or Mod GRF — lacks the albumin-binding modification and has a much shorter half-life of approximately 30 minutes. Researchers studying the two compounds use them for different experimental contexts depending on whether sustained or pulsatile GH stimulation is the research objective. Our Advanced Guide on Peptide Half-Life explains how these pharmacokinetic differences affect research design.
What the Research Shows
CJC-1295 research has focused primarily on its ability to produce sustained, dose-dependent increases in plasma GH and IGF-1 levels in controlled study models. Early clinical research demonstrated that single doses produced GH elevations lasting several days — a profile that had not previously been achieved with GHRH analogs and that opened new possibilities for studying the downstream effects of sustained GH pathway activation.
Research has examined CJC-1295 across several areas including metabolic function, body composition models, and tissue biology. Because GH and IGF-1 have broad effects across multiple organ systems — influencing protein synthesis, fat metabolism, bone density, and cellular repair processes — the downstream research applications of sustained GHRH receptor agonism are correspondingly wide.
CJC-1295 is also frequently studied in combination with ghrelin mimetics like Ipamorelin, which stimulate GH release through a separate receptor pathway. The rationale for combination research is that GHRH and ghrelin act synergistically at the pituitary level — activating complementary pathways that together produce a more robust GH pulse than either compound achieves independently. For context on how research studies investigating compounds like these are designed and interpreted, our How Research Studies Are Designed guide is a useful reference.
CJC-1295 vs Modified GRF(1-29): Understanding the Difference
One of the most common sources of confusion in CJC-1295 research is the distinction between CJC-1295 with DAC and CJC-1295 without DAC — the latter of which is more accurately called Modified GRF(1-29) or Mod GRF.
Both compounds share the same 29-amino acid GHRH backbone with four amino acid substitutions designed to improve stability and receptor affinity compared to native GHRH. The critical difference is the DAC modification. With DAC, the compound binds albumin and achieves a week-long half-life — producing what researchers call a “GH bleed,” a sustained low-level elevation of GH over several days. Without DAC, the compound has a half-life closer to 30 minutes and produces a more discrete, pulsatile GH release pattern.
These are fundamentally different pharmacokinetic profiles with different research applications. Sustained GH elevation models use CJC-1295 with DAC. Pulsatile GH secretion models — which more closely mimic natural physiological GH release patterns — use Mod GRF(1-29), often paired with a ghrelin mimetic timed to create a natural-style GH pulse. Understanding which version is being referenced in research literature is essential for correctly interpreting study findings.
CJC-1295 in the Growth Hormone Research Landscape
CJC-1295 occupies a well-established position in the growth hormone research landscape as the most extensively studied long-acting GHRH analog. It serves as a reference compound for researchers investigating sustained GHRH receptor agonism and its downstream effects on GH and IGF-1 biology.
Its research profile is complemented by ghrelin mimetics — particularly Ipamorelin, which is selective for the GH secretagogue receptor (GHSR) and is frequently studied alongside CJC-1295 for its ability to stimulate GH release through a complementary pathway without significantly affecting cortisol or prolactin levels. Together, CJC-1295 and Ipamorelin represent the two most commonly paired compounds in growth hormone axis research.
For researchers building out a broader understanding of the growth hormone axis, the MOTS-C research overview provides relevant context on mitochondrial-derived peptides and their intersection with metabolic signaling — a related but distinct area of the GH/metabolism research space. BioStrata Research’s MOTS-C — 10mg is available as a research-grade compound for qualified laboratory use alongside our full Metabolic Research catalog.
FAQ — CJC-1295 Research
What is CJC-1295? CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) — the hypothalamic signal that triggers growth hormone release from the pituitary gland. It was engineered with a Drug Affinity Complex (DAC) modification that allows it to bind albumin in the bloodstream, extending its half-life from minutes to approximately 6–8 days. It is used in research investigating sustained GHRH receptor agonism and its downstream effects on GH and IGF-1 biology.
What is the difference between CJC-1295 with DAC and without DAC? CJC-1295 with DAC binds albumin and has a half-life of approximately 6–8 days, producing sustained GH elevation. CJC-1295 without DAC — more accurately called Modified GRF(1-29) — has a half-life of around 30 minutes and produces a more pulsatile GH release pattern. They are used for different research applications depending on whether sustained or pulsatile GH stimulation is the study objective.
Why is CJC-1295 often researched with Ipamorelin? CJC-1295 stimulates GH release through the GHRH receptor. Ipamorelin stimulates GH release through the ghrelin receptor (GHSR) — a separate pathway. Because these two pathways act synergistically at the pituitary level, combining them in research models produces a more robust GH pulse than either compound achieves independently. This combination is one of the most studied pairings in growth hormone axis research.
What does CJC-1295 research focus on? Research has examined CJC-1295’s effects on plasma GH and IGF-1 levels, body composition models, metabolic function, and tissue biology. Because GH and IGF-1 influence protein synthesis, fat metabolism, bone density, and cellular repair, the downstream research applications of sustained GHRH receptor agonism are broad.
Does BioStrata Research carry CJC-1295? CJC-1295 is not currently in our catalog, but we carry a growing range of research-grade metabolic and signaling peptides. Browse our full Research Catalog or contact our team if you’re looking for a specific compound not currently listed.
- CONTINUE LEARNING
Explore Related Peptide Topics
Continue building your understanding by exploring related foundational peptide topics.